{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:34:23Z","timestamp":1778510063676,"version":"3.51.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/ftd.0b013e318286dd3f","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T10:41:41Z","timestamp":1368182501000},"page":"332-337","source":"Crossref","is-referenced-by-count":34,"title":["Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1"],"prefix":"10.1097","volume":"35","author":[{"given":"Jeffrey R.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Courter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon N.","family":"Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Perentesis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":". Neurofibromatosis type 1 revisited.","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-144-11-200606060-00010","article-title":"Pathophysiology of neurofibromatosis type 1.","volume":"144","author":"Theos","year":"2006","journal-title":"Ann Intern Med"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","article-title":"Plexiform neurofibromas.","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.5-6-477","article-title":"Malignancy in neurofibromatosis type 1.","volume":"5","author":"Korf","year":"2000","journal-title":"Oncologist"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","article-title":". Prognostic signs in the surgical management of plexiform neurofibroma: the Childrens Hospital of Philadelphia experience, 1974-1994.","volume":"131","author":"Needle","year":"1997","journal-title":"J Pediatr"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.yexcr.2003.12.032","article-title":"Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration.","volume":"296","author":"Berven","year":"2004","journal-title":"Exp Cell Res"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":". Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus.","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1038\/sj.onc.1209691","article-title":". Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.","volume":"25","author":"Liu","year":"2006","journal-title":"Oncogene"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-05-2170","article-title":". Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.","volume":"12","author":"Namba","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth.","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":". mTOR-targeted therapy of cancer with rapamycin derivatives.","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1593\/neo.05820","article-title":". CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTORHif-1alphaVEGF signaling.","volume":"8","author":"Wan","year":"2006","journal-title":"Neoplasia"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","article-title":". Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":". The NF1 tumor suppressor critically regulates TSC2 and mTOR.","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"re15","DOI":"10.1126\/stke.2122003re15","article-title":"TOR signaling.","volume":"2003","author":"Harris","year":"2003","journal-title":"Sci STKE"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease.","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrm1018","article-title":"Tor signalling in bugs, brain and brawn.","volume":"4","author":"Jacinto","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2125.2005.02533.x","article-title":". A Bayesian approach for population pharmacokinetic modelling of sirolimus.","volume":"62","author":"Dansirikul","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1399-3046.2003.00148.x","article-title":". Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.","volume":"8","author":"Schachter","year":"2004","journal-title":"Pediatr Transplant"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1399-3046.2006.00541.x","article-title":". Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.","volume":"10","author":"Schachter","year":"2006","journal-title":"Pediatr Transplant"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2005.00745.x","article-title":". Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.","volume":"5","author":"Anglicheau","year":"2005","journal-title":"Am J Transplant"},{"issue":"suppl B","key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"B86","DOI":"10.1016\/S0149-2918(00)89025-6","article-title":"Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation.","volume":"22","author":"Aspeslet","year":"2000","journal-title":"Clin Ther"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200645110-00007","article-title":". Sirolimus population pharmacokineticpharmacogenetic analysis and Bayesian modelling in kidney transplant recipients.","volume":"45","author":"Djebli","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"suppl B","key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","article-title":". Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.","volume":"22","author":"MacDonald","year":"2000","journal-title":"Clin Ther"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/j.1552-4604.1997.tb04318.x","article-title":"Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.","volume":"37","author":"Zimmerman","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":". Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-4825(92)90011-B","article-title":"MWPharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.","volume":"22","author":"Proost","year":"1992","journal-title":"Comput Biol Med"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans.","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1152\/physrev.1947.27.4.511","article-title":"Body size and metabolic rate.","volume":"27","author":"Kleiber","year":"1947","journal-title":"Physiol Rev"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics.","volume":"30","author":"Holford","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1399-3046.2003.00137.x","article-title":". Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.","volume":"8","author":"Tejani","year":"2004","journal-title":"Pediatr Transplant"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1600-6143.2004.00411.x","article-title":". Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.","volume":"4","author":"Schubert","year":"2004","journal-title":"Am J Transplant"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clpt.2006.03.012","article-title":". CYP3A53 influences sirolimus oral clearance in de novo and stable renal transplant recipients.","volume":"80","author":"Le Meur","year":"2006","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318286dd3f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T18:05:00Z","timestamp":1645034700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201306000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318286dd3f","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}